Mirdametinib for histiocytic disorders
Treatments studied
Part of Blood & lymphatic, Lungs & breathing, Skin clinical trials.
This trial tests a drug called mirdametinib for people with histiocytic disorders, which are rare diseases where certain immune cells grow out of control. It may help shrink tumors and improve symptoms when other treatments haven't worked.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 2 years old and have a histiocytic disorder that needs treatment.
- Your disease must be visible on a PET scan or brain MRI.
- Your kidneys, liver, and blood counts must be within certain safe limits.
- You cannot have taken certain chemotherapy or steroids within 14 days before starting the study drug.
- You cannot have had a MEK inhibitor within 30 days or have had the disease worsen while on it.
- You must not have certain eye, heart, or blood pressure problems, and you must be willing to use birth control if needed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called Luvometinib added to a standard chemotherapy regimen for children with Langerhans cell histiocytosis that affects multiple parts of the body. The goal is to see if the combination works better than the standard treatment alone.
This trial tests the drug luvometinib for children with a specific type of bone disease called Langerhans cell histiocytosis (LCH). It may help kids who have not been treated before and whose LCH is in certain bones, including the head, face, or spine.
This trial tests a drug called mirdametinib for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that has come back or not responded to at least two prior treatments, including a BTK inhibitor and a BCL2 inhibitor. The goal is to see if mirdametinib can help shrink the cancer or slow its growth.
This trial tests a drug called mirdametinib for people with specific types of brain tumors or neurohistiocytosis (a rare condition affecting the nervous system). The drug targets mutations that cause these conditions to grow.
This Phase 2 trial studies cobimetinib, a medicine that targets a specific growth-and-signal pathway, to treat stubborn (refractory or worsening) Langerhans cell histiocytosis and related disorders. It may help shrink active disease or stop disease from progressing.
This Phase 1/2 trial tests how safe and how well a combination of chemo and immunotherapy works when followed by a short course of a targeted “MEK” inhibitor as first treatment for metastatic lung adenocarcinoma with PD-L1 below 50%. It may help some people control cancer better, while also providing more information about side effects and the best way to use these medicines together.
Hear when a new Langerhans Cell Histiocytosis (LCH) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.